ZA200905306B - Use of LHRH antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity - Google Patents

Use of LHRH antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity

Info

Publication number
ZA200905306B
ZA200905306B ZA200905306A ZA200905306A ZA200905306B ZA 200905306 B ZA200905306 B ZA 200905306B ZA 200905306 A ZA200905306 A ZA 200905306A ZA 200905306 A ZA200905306 A ZA 200905306A ZA 200905306 B ZA200905306 B ZA 200905306B
Authority
ZA
South Africa
Prior art keywords
treatment
urinary tract
overactive bladder
lower urinary
tract symptoms
Prior art date
Application number
ZA200905306A
Other languages
English (en)
Inventor
Juergen Engel
Oliver Bauer
Original Assignee
Aeterna Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeterna Zentaris Gmbh filed Critical Aeterna Zentaris Gmbh
Publication of ZA200905306B publication Critical patent/ZA200905306B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA200905306A 2007-03-05 2009-07-30 Use of LHRH antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity ZA200905306B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07103483A EP1967202A1 (en) 2007-03-05 2007-03-05 Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity

Publications (1)

Publication Number Publication Date
ZA200905306B true ZA200905306B (en) 2010-04-28

Family

ID=38006763

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200905306A ZA200905306B (en) 2007-03-05 2009-07-30 Use of LHRH antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity

Country Status (13)

Country Link
US (1) US20090075937A1 (xx)
EP (2) EP1967202A1 (xx)
JP (1) JP2010520257A (xx)
KR (1) KR20100014923A (xx)
CN (1) CN101657211A (xx)
AU (1) AU2008223841A1 (xx)
BR (1) BRPI0808488A2 (xx)
CA (1) CA2679690A1 (xx)
IL (1) IL200182A0 (xx)
MX (1) MX2009009320A (xx)
RU (1) RU2009136642A (xx)
WO (1) WO2008107446A1 (xx)
ZA (1) ZA200905306B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2704298C (en) 2007-11-02 2015-07-21 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
US8778998B2 (en) 2009-04-10 2014-07-15 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
EP2424503B1 (en) 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
EP2266567A1 (en) * 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
EP2266568A1 (en) * 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
KR20130135239A (ko) * 2010-08-03 2013-12-10 앨씨알엑스, 인크. 과민성 방광 치료를 위한 베타-3 아드레날린 수용체 작용제 및 무스카린 수용체 길항제의 약학적 배합제
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
PL2632934T3 (pl) 2010-10-27 2017-06-30 Ferring B.V. Sposób wytwarzania degareliksu i jego związków pośrednich
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
AR092840A1 (es) 2012-06-01 2015-05-06 Ferring Bv Elaboracion de degarelix
BR112015005351A2 (pt) 2012-09-18 2017-07-04 Taris Biomedical Llc sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
PT3365321T (pt) 2015-10-23 2024-01-12 B3Ar Therapeutics Inc Zwiterião de solabegron e suas utilizações
BR112021001337A2 (pt) 2018-08-01 2021-04-20 Taris Biomedical Llc métodos de tratamento de bexiga hiperativa usando tróspio

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
NZ536787A (en) * 1998-06-11 2006-03-31 Endorech Inc Pharmaceutical compositions and uses for androst-5-ene-3beta,17beta diol
AU2001295359A1 (en) * 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
RU2319692C2 (ru) * 2001-12-14 2008-03-20 Центарис Гмбх Производные тетрагидрокарбазола, способ получения производных тетрагидрокарбазола (варианты), их применение (варианты) и фармацевтическая композиция, обладающая активностью антагониста гонадотропин-рилизинг-гормона (варианты)
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
DE102004033902A1 (de) * 2004-07-14 2006-02-16 Zentaris Gmbh Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)

Also Published As

Publication number Publication date
US20090075937A1 (en) 2009-03-19
IL200182A0 (en) 2010-04-15
EP1967202A1 (en) 2008-09-10
MX2009009320A (es) 2009-09-10
EP2131854A1 (en) 2009-12-16
CN101657211A (zh) 2010-02-24
AU2008223841A1 (en) 2008-09-12
JP2010520257A (ja) 2010-06-10
RU2009136642A (ru) 2011-04-10
WO2008107446A1 (en) 2008-09-12
BRPI0808488A2 (pt) 2014-07-15
KR20100014923A (ko) 2010-02-11
CA2679690A1 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
IL200182A0 (en) Use of lhrh antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity
AP2011005672A0 (en) Pyrazolopyrimidines and their use for the treatment of CNS disorders.
EP2087094A4 (en) LACTOBACILLUS FERMENTUM ESS-1, DSM17851 AND ITS USE IN THE TREATMENT AND / OR PREVENTION OF CANDIDOSIS AND URINARY TRACT INFECTIONS
PT2162118T (pt) Microesferas porosas e sua utilização em terapia
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
PL1912650T3 (pl) Zastosowanie flibanseryny w leczeniu otyłości
IL181369A0 (en) Herbal compositions for the prevention or treatment of urinary incontinence and overactive bladder
HK1215683A1 (zh) 抗葉酸藥在癌症治療中的聯合應用
IL202674A0 (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
IL198461A (en) 3 alpha androstandiol and type 5 phosphodiesterase inhibitor (pde5 for on-demand use in the treatment of sexual dysfunction
IL215583A0 (en) Methods for preventing and/or treating lysosomal storage disorders
WO2009024667A3 (fr) Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
IL205680A0 (en) Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
HK1134032A1 (en) New combination for use in the treatment of inflammatory disorders
GB2460181B (en) Depsipeptides and their therapeutic use
EP2121785A4 (en) SYDNONIMINES - INHIBITORS FOR SPECIFIC DOPAMINE REABSORPTION AND THEIR USE IN THE TREATMENT OF DOPAMINE-RELATED DISORDERS
IL208385A0 (en) Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder
EP2313165A4 (en) BALL FOR PLAY AND / OR TRAINING
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
GB0718824D0 (en) Methods of treating lysosomal storage disorders
GB0607199D0 (en) Improved ball valve and valve seat
GB2460180B (en) Depsipeptides and their therapeutic use
WO2009046123A3 (en) Nlrr-1 antagonists and uses thereof
ZA200904382B (en) Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-retaled diseases